Dr Adam Stewart
Dr

Adam Stewart

Email: 

Background

Adam G. Stewart, BBiomedSci, MBBS (Hons), MPHTM, FRACP, FRCPA, PhD

Dr Adam Stewart is is an Australian-trained Infectious Diseases Physician and Clinical Microbiologist. He is currently working on clinical faculty as an Assistant Professor at the University of Texas MD Anderson Cancer Center in Houston, USA. He has previously undertaken post-fellowship subspeciality training in Transplant Infectious Diseases at Massachusetts General Hospital and Harvard University. Dr Stewart is an active physician-scientist with interests in clinical trials, invasive fungal disease, and infections in oncology and transplant patients. Dr Stewart is committed to advancing the management of infections in cancer patients.

Availability

Dr Adam Stewart is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Biomedical Science, Griffith University
  • Bachelor of Medicine and Surgery and Medical Science, Griffith University
  • Masters (Coursework) of Public Health and Tropical Medicine, James Cook University

Research interests

  • Invasive fungal disease

    Clinical and translational research on the causes of early treatment failure and refractory infection in haematological malignancy patients

  • Fungal diagnostics

    Fungal pathogenesis research; host and pathogen biomarker discovery for clinical use for diagnostic and prognostic purposes

  • Clinical trials

    Novel clinical trial design for rare or uncommon pathogens including those causing invasive fungal disease

Search Professor Adam Stewart’s works on UQ eSpace

96 works between 2015 and 2026
All (96) Journal Article (93) Other Outputs (1) Conference Publication (2)

61 - 80 of 96 works

2021

Journal Article

Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial

Stewart, Adam G., Harris, Patrick N. A., Chatfield, Mark D., Littleford, Roberta and Paterson, David L. (2021). Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial. Trials, 22 (1) 301, 301. doi: 10.1186/s13063-021-05206-8

Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial

2021

Journal Article

An update on the laboratory diagnosis of Rickettsia spp. infection

Stewart, Adam G. and Stewart, Alexandra G. A. (2021). An update on the laboratory diagnosis of Rickettsia spp. infection. Pathogens, 10 (10) 1319, 1319. doi: 10.3390/pathogens10101319

An update on the laboratory diagnosis of Rickettsia spp. infection

2021

Journal Article

An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa–—authors’ response

Isler, Burcu, Harris, Patrick, Stewart, Adam G. and Paterson, David L. (2021). An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa–—authors’ response. Journal of Antimicrobial Chemotherapy, 76 (12), 3327-3328. doi: 10.1093/jac/dkab366

An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa–—authors’ response

2021

Journal Article

Cryptococcus neoformans infection as a cause of severe hyperammonaemia and encephalopathy

Stewart, Adam G., Sinclair, Holly, Chapman, Paul, Baboolal, Keshwar, Barber, Bridget E. and Townsend, Shane (2021). Cryptococcus neoformans infection as a cause of severe hyperammonaemia and encephalopathy. Internal Medicine Journal, 51 (10), 1750-1751. doi: 10.1111/imj.15516

Cryptococcus neoformans infection as a cause of severe hyperammonaemia and encephalopathy

2021

Journal Article

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC beta-lactamase producing Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp., or Serratia marcescens: a pilot multi-center randomized controlled trial (MERINO-2)

Stewart, Adam G., Paterson, David L., Young, Barnaby, Lye, David C, Davis, Joshua S., Schneider, Kellie, Yilmaz, Mesut, Dinleyici, Rumeysa, Runnegar, Naomi, Henderson, Andrew, Archuleta, Sophia, Kalimuddin, Shirin, Forde, Brian M., Chatfield, Mark D., Bauer, Michelle J., Lipman, Jeffrey, Harris-Brown, Tiffany, Harris, Patrick N. A. and for the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN) (2021). Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC beta-lactamase producing Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp., or Serratia marcescens: a pilot multi-center randomized controlled trial (MERINO-2). Open Forum Infectious Diseases, 8 (8) ofab387, ofab387. doi: 10.1093/ofid/ofab387

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC beta-lactamase producing Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp., or Serratia marcescens: a pilot multi-center randomized controlled trial (MERINO-2)

2021

Journal Article

Prolonged granulocyte transfusions sourced from buffy coats used to treat Aspergillus spp. infection in chronic granulomatous disease

Stewart, Adam G., Baidya, Shoma, Daly, James and Scott, Ashleigh P. (2021). Prolonged granulocyte transfusions sourced from buffy coats used to treat Aspergillus spp. infection in chronic granulomatous disease. Pathology, 54 (3), 358-361. doi: 10.1016/j.pathol.2021.05.098

Prolonged granulocyte transfusions sourced from buffy coats used to treat Aspergillus spp. infection in chronic granulomatous disease

2021

Journal Article

In vitro activity of Cefotetan against ESBL-producing Escherichia coli and Klebsiella pneumoniae bloodstream isolates from the MERINO Trial

Stewart, Adam G., Cottrell, Kyra, Henderson, Andrew, Vemuri, Kanthi, Bauer, Michelle J., Paterson, David L. and Harris, Patrick N. A. (2021). In vitro activity of Cefotetan against ESBL-producing Escherichia coli and Klebsiella pneumoniae bloodstream isolates from the MERINO Trial. Microbiology Spectrum, 9 (1) e00226-21, 1-6. doi: 10.1128/spectrum.00226-21

In vitro activity of Cefotetan against ESBL-producing Escherichia coli and Klebsiella pneumoniae bloodstream isolates from the MERINO Trial

2021

Journal Article

New microbiological techniques for the diagnosis of bacterial infections and sepsis in ICU including point of care

Peri, Anna Maria, Stewart, Adam, Hume, Anna, Irwin, Adam and Harris, Patrick N A (2021). New microbiological techniques for the diagnosis of bacterial infections and sepsis in ICU including point of care. Current Infectious Disease Reports, 23 (8) 12, 12. doi: 10.1007/s11908-021-00755-0

New microbiological techniques for the diagnosis of bacterial infections and sepsis in ICU including point of care

2021

Journal Article

Completing the picture - capturing the resistome in antibiotic clinical trials

Stewart, Adam G., Satlin, Michael J., Schlebusch, Sanmarié, Isler, Burcu, Forde, Brian M., Paterson, David L. and Harris, Patrick N. A. (2021). Completing the picture - capturing the resistome in antibiotic clinical trials. Clinical Infectious Diseases, 72 (12), e1122-e1129. doi: 10.1093/cid/ciaa1877

Completing the picture - capturing the resistome in antibiotic clinical trials

2021

Journal Article

Listeria monocytogenes brain abscess as a late complication of allogeneic haemopoietic stem cell transplantation

Chung, Joseph, McCarthy, Kate L., Redmond, Andrew, Butler, Jason, Scott, Ashleigh P. and Stewart, Adam G. (2021). Listeria monocytogenes brain abscess as a late complication of allogeneic haemopoietic stem cell transplantation. Internal Medicine Journal, 51 (6), 1005-1006. doi: 10.1111/imj.15356

Listeria monocytogenes brain abscess as a late complication of allogeneic haemopoietic stem cell transplantation

2021

Journal Article

Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae in Southeast Queensland, Australia

Stewart, A. G., Price, E. P., Schabacker, K., Birikmen, M., Harris, P. N. A., Choong, K., Subedi, S. and Sarovich, D. S. (2021). Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae in Southeast Queensland, Australia. Antimicrobial Agents and Chemotherapy, 65 (6) e00130-21, 1-13. doi: 10.1128/AAC.00130-21

Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae in Southeast Queensland, Australia

2021

Journal Article

Just as good but better tolerated: posaconazole as first-line therapy for invasive aspergillosis

Stewart, Adam G. and Lane, Steven (2021). Just as good but better tolerated: posaconazole as first-line therapy for invasive aspergillosis. The Hematologist, 18 (3).

Just as good but better tolerated: posaconazole as first-line therapy for invasive aspergillosis

2021

Journal Article

How urgent is the need for new antifungals?

Stewart, Adam G. and Paterson, David L. (2021). How urgent is the need for new antifungals?. Expert Opinion on Pharmacotherapy, 22 (14), 1-14. doi: 10.1080/14656566.2021.1935868

How urgent is the need for new antifungals?

2021

Journal Article

Infectious complications of CAR T-cell therapy: a clinical update

Stewart, Adam G. and Henden, Andrea S. (2021). Infectious complications of CAR T-cell therapy: a clinical update. Therapeutic Advances in Infectious Disease, 8 204993612110367, 1-11. doi: 10.1177/20499361211036773

Infectious complications of CAR T-cell therapy: a clinical update

2020

Journal Article

An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa

Isler, Burcu, Harris, Patrick, Stewart, Adam G. and Paterson, David L. (2020). An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. The Journal of Antimicrobial Chemotherapy, 76 (3), 550-560. doi: 10.1093/jac/dkaa511

An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa

2020

Journal Article

Achromobacter infections and treatment options

Isler, Burcu, Kidd, Timothy J., Stewart, Adam G., Harris, Patrick and Paterson, David L. (2020). Achromobacter infections and treatment options. Antimicrobial Agents and Chemotherapy, 64 (11) e01025, 1-16. doi: 10.1128/aac.01025-20

Achromobacter infections and treatment options

2020

Journal Article

Is ceftazidime/avibactam an option for serious infections due to ESBL and AmpC producing Enterobacterales?: a systematic review and meta-analysis

Isler, Burcu, Ezure, Yukiko, García-Fogeda Romero, Jose Luis, Harris, Patrick, Stewart, Adam G. and Paterson, David L. (2020). Is ceftazidime/avibactam an option for serious infections due to ESBL and AmpC producing Enterobacterales?: a systematic review and meta-analysis. Antimicrobial Agents and Chemotherapy, 65 (1) e01052-20. doi: 10.1128/AAC.01052-20

Is ceftazidime/avibactam an option for serious infections due to ESBL and AmpC producing Enterobacterales?: a systematic review and meta-analysis

2020

Journal Article

Whole genome sequencing for antimicrobial resistance mechanisms, virulence factors and clonality in invasive Streptococcus agalactiae blood culture isolates recovered in Australia

Stewart, Adam G., Burnard, Delaney, Sowden, David and McMillan, David (2020). Whole genome sequencing for antimicrobial resistance mechanisms, virulence factors and clonality in invasive Streptococcus agalactiae blood culture isolates recovered in Australia. Pathology, 52 (6), 694-699. doi: 10.1016/j.pathol.2020.06.006

Whole genome sequencing for antimicrobial resistance mechanisms, virulence factors and clonality in invasive Streptococcus agalactiae blood culture isolates recovered in Australia

2020

Journal Article

Modern clinician-initiated clinical trials to determine optimal therapy for multi-drug resistant Gram-negative infections

Stewart, Adam G., Harris, Patrick N. A., Chatfield, Mark, Evans, Scott R., van Duin, David and Paterson, David L. (2020). Modern clinician-initiated clinical trials to determine optimal therapy for multi-drug resistant Gram-negative infections. Clinical Infectious Diseases, 71 (2), 433-439. doi: 10.1093/cid/ciz1132

Modern clinician-initiated clinical trials to determine optimal therapy for multi-drug resistant Gram-negative infections

2020

Journal Article

Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections

Stewart, Adam G., Harris, Patrick N. A., Henderson, Andrew, Schembri, Mark A. and Paterson, David L. (2020). Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. Journal of Antimicrobial Chemotherapy, 75 (9), 2384-2393. doi: 10.1093/jac/dkaa183

Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections

Past funding

  • 2020 - 2022
    Assessing in vitro activity of oral third generation cephalosporin / beta-lactamase inhibitor combinations against extended spectrum beta-lactamase (ESBL) producing uropathogens
    The Royal College of Pathologists of Australasia
    Open grant
  • 2020 - 2021
    USE OF THERAPEUTIC DRUG MONITORING (TDM) TO OPTIMISE ORAL/ENTERAL HYDROXYCHLOROQUINE DOSING IN CRITICALLY ILL PATIENTS WITH COVID-19 (MRFF CRR Respiratory Medicine administered by QUT)
    Queensland University of Technology
    Open grant
  • 2020 - 2025
    COVID-19 Cure Research (Paterson)
    Royal Brisbane and Women's Hospital Foundation
    Open grant
  • 2020 - 2021
    Assessing the effects of new and old antibiotics on gut microbiota of hospitalized patients
    Avant Mutual Group Limited
    Open grant
  • 2020 - 2021
    Assessing the effects of new and old antibiotics on the gut microbiome of hospitalized patients
    Metro North Hospital and Health Service
    Open grant
  • 2019 - 2022
    A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of ceftolozane-tazobactam versus meropenem for definitive treatment [...] MERINO-3
    Merck Sharp & Dohme Australia
    Open grant
  • 2018 - 2021
    A multicentre, Parallel Group Open-label RC Non-Inferiority Trial of piperacillin-tazobactam versus meropenem for definitive treatment of bloodstream infection due to AmpC-producing Enterobacterales
    Junior Doctor Research Fellowships
    Open grant

Availability

Dr Adam Stewart is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Enquiries

Contact Dr Adam Stewart directly for media enquiries about:

  • clinical trial
  • infectious diseases
  • superbugs

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au